Neural Tissue Units With Partial Hydrogel Removal for Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, such as Parkinson's and Huntington's, face challenges with low survival rates of implanted neuronal cells and uncontrolled differentiation, leading to ethical issues and inefficacy in replacing damaged neurons.
Innovation Solution
A neural tissue unit comprising post-mitotic neuronal cells organized in a 3D network within an extracellular matrix, encapsulated in a hydrogel capsule, which is partially removed before implantation to promote integration and controlled differentiation, enhancing survival and functional integration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If neuronal cells are injected as a suspension, then the implantation process is simple, but the survival rate of implanted neurons is extremely low (more than 98% die by anoikis)
Solution Approach 1:
The patent applies preliminary action by pre-organizing neuronal cells into three-dimensional microtissues with extracellular matrix and supportive cells before implantation. This pre-organization creates a protective microenvironment that prevents anoikis and ensures cell survival, resolving the contradiction between operational simplicity and survival rate.
2Reliability
If neuronal progenitors are transplanted instead of mature neurons, then cell fragility is reduced, but differentiation control is lost and desired neuronal types cannot be guaranteed
Solution Approach 1:
The patent performs differentiation in advance during in vitro cultivation, generating mature post-mitotic neurons with specific phenotypes before implantation. This preliminary differentiation ensures both cell robustness and precise phenotypic control, eliminating the need for post-implantation differentiation control.
Solution Approach 2:
The patent uses parameter changes by controlling cultivation conditions (growth factors, substrate composition, cell density) to direct differentiation toward specific neuronal phenotypes. This allows precise control over the type of neurons generated while maintaining their robustness through maturation in a controlled environment.
3Reliability
If tissue from aborted fetuses is used for transplantation, then neuronal replacement can be achieved, but ethical and logistical issues arise
Solution Approach 1:
The patent uses copying by generating neurons in vitro from pluripotent stem cells that can be differentiated into specific neuronal types. This creates a renewable, ethically acceptable source of neurons that replicates the therapeutic effect of fetal tissue transplantation without the associated ethical and logistical problems.
4Reliability
If the hydrogel capsule is completely removed before implantation, then integration into host tissue is maximized, but protection during handling is lost
Solution Approach 1:
The patent applies partial action by partially degrading the hydrogel capsule rather than completely removing it. This partial degradation maintains sufficient protection during handling while allowing adequate integration with host tissue, resolving the contradiction between protection and integration.
Data Source
AI summary
The invention relates to a neural tissue unit for use in implantation into the nervous system of a human or non-human mammal, wherein said neural tissue unit contains differentiated post-mitotic neuronal cells in an extracellular matrix, said unit being obtained from a cellular microcompartment comprising a hydrogel capsule surrounding the neural tissue unit, and said hydrogel capsule being at least partially removed before use of the neural tissue unit. The invention also relates to a process for preparing such a neural tissue unit.